The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III ...

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in ...

By HOWARD FENDRICH AP Tennis Writer Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her first Grand Slam competition in two years.

Sjögren, who is currently head coach of Hammarby in Sweden’s top women’s flight, will join the club in January.

Jill M. Kramer, DDS, PhD, associate professor in the Department of Oral Biology at the University at Buffalo School of Dental ...

The Chicago Stars have named former Norway women’s national team coach Martin Sjögren as the National Women’s Soccer League ...